The US biotechnology company Regeneron Pharmaceuticals Inc. said a single dose of the antibody cocktail it developed reduced the risk of COVID-19 infection by 81.6 percent two to eight months after taking it, Reuters reported.
This is shown by data from the last phase of clinical trials of RegEN-COV therapy.
“They indicate that the drug has the potential to provide long-term immunity against COVID-19 infection,” said Myron Cohen, team leader who develops monoclonal antibodies for the Covid Prevention Network, supported by the US National Institutes of Health.
This is especially important for people with compromised immune systems and for those who do not respond to vaccines, the company said.
In previous studies, the company’s monoclonal antibody cocktail showed 81.4 percent effectiveness in reducing the risk of infection within the first month after ingestion.
During the eight-month studies, no patient taking the drug was admitted to hospital for COVID-19 compared to six of the volunteers who took placebo.